Atea Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Atea Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2019 to Q3 2024.
  • Atea Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $12.2M, a 1.77% decline year-over-year.
  • Atea Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $49.6M, a 1.45% increase year-over-year.
  • Atea Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $49.4M, a 5.8% increase from 2022.
  • Atea Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $46.7M, a 17.9% increase from 2021.
  • Atea Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $39.6M, a 431% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $49.6M $12.2M -$219K -1.77% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $49.8M $12.7M +$367K +2.97% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $49.5M $12.6M +$51K +0.41% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $49.4M $12.2M +$512K +4.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $48.9M $12.4M +$879K +7.64% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $48M $12.4M +$445K +3.74% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $47.6M $12.5M +$874K +7.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $46.7M $11.6M +$294K +2.59% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $46.4M $11.5M +$514K +4.68% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $45.9M $11.9M +$1.9M +19% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $44M $11.7M +$4.39M +60.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $39.6M $11.4M +$8.53M +302% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 $31.1M $11M +$6.75M +159% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $24.3M $10M +$9.8M +4688% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $14.5M $7.27M +$7.08M +3748% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $7.46M $2.82M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $4.24M +$4.08M +2599% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $209K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $189K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q3 2019 $157K Jul 1, 2019 Sep 30, 2019 10-Q 2020-12-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.